ArticleJournal of pharmaceutical health care and sciences2026
Predictors of target initial teicoplanin trough concentration attainment in patients with hematological malignancies: a retrospective cohort study.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTeicoplanin (TEIC) is frequently used at Osaka Metropolitan University Hospital to treat infections caused by gram-positive cocci in patients with hematological malignancies. However, in certain cases, the initial trough concentrations failed to reach the target level, despite appropriate loading doses. Therefore, this study aimed to identify the factors associated with achieving target concentrations based on the initial trough level following TEIC loading in patients with hematological malignancies.
methodsWe retrospectively analyzed patients with hematological malignancies treated with TEIC between January 2016 and December 2022. Patients were classified into a target trough attainment group (trough ≥ 15 µg/mL) and a non-attainment group (trough < 15 µg/mL) according to the initial trough concentration measured on day 4 after administering the loading doses. Demographics, clinical laboratory data, TEIC dosing, and concomitant medications were compared between groups. Factors independently associated with the target trough concentration were assessed using multivariate logistic regression analysis.
resultsAmong the 176 patients, 90 (51%) achieved the target trough concentration, while 86 (49%) did not. Multivariate analysis identified febrile neutropenia, history of bone marrow transplantation within 30 days, presence or absence of tacrolimus (TAC) coadministration, and cumulative TEIC dose over the first 3 days as independent predictors of target attainment. The target concentration attainment rate was only 22% among patients with febrile neutropenia who received a TEIC cumulative loading dose of < 40 mg/kg over the first 3 days after initiation and did not receive TAC coadministration.
conclusionsAchieving adequate TEIC concentrations early in therapy is critical for the successful treatment of immunocompromised patients with hematological malignancies. Our findings indicated that the likelihood of target trough concentration attainment markedly reduced in patients with multiple risk factors for subtherapeutic exposure. Accordingly, higher doses should be administered, particularly to patients with these factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.